Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that preclinical data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.
Linnaeus Therapeutics Awarded $300,000 Phase 1 STTR by National Cancer Institute Haddonfield NJ, March 16, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 1 Small Business [...]
Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.
